MARKET

PRQR

PRQR

Proqr Therapeuti
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.6425
-0.0455
-6.61%
Opening 12:02 05/24 EDT
OPEN
0.6748
PREV CLOSE
0.6880
HIGH
0.6880
LOW
0.6321
VOLUME
284.08K
TURNOVER
155.04K
52 WEEK HIGH
9.09
52 WEEK LOW
0.5300
MARKET CAP
45.80M
P/E (TTM)
-0.5872
1D
5D
1M
3M
1Y
5Y
--HC Wainwright Lowers ProQR Therapeutics N.V's Price Target to $2 From $4, Buy Rating Kept
MT Newswires · 05/09 11:28
ProQR to Present its Axiomer® RNA Editing Technology at the Oligonucleotide and Peptide Therapeutics Conference (TIDES USA) 2022
LEIDEN, Netherlands & CAMBRIDGE, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies, today announced a presentation at t...
GlobeNewswire · 05/09 11:00
Expert Ratings for ProQR Therapeutics
Within the last quarter, ProQR Therapeutics (NASDAQ:PRQR) has observed the following analyst ratings:
Benzinga · 05/06 14:04
--Chardan Lowers Price Target for ProQR Therapeutics N.V to $2 From $2.50, Maintains Buy Rating
MT Newswires · 05/06 11:01
ProQR (PRQR) Reports Q1 Loss, Tops Revenue Estimates
ProQR (PRQR) delivered earnings and revenue surprises of 12% and 16.39%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/06 00:15
ProQR Therapeutics Q1 EPS €(0.20) Up From €(0.30) YoY, Sales €1.23M Up From €170.03K YoY
ProQR Therapeutics (NASDAQ:PRQR) reported quarterly losses of $(0.20) per share. This is a 33.33 percent increase over losses of $(0.30) per share from the same period last year. The company reported $1.23 million in
Benzinga · 05/05 21:38
ProQR GAAP EPS of -€0.20, revenue of €1.23M
ProQR press release (NASDAQ:PRQR): Q1 GAAP EPS of -€0.20. Revenue of €1.23M.
Seekingalpha · 05/05 21:10
BRIEF-Proqr Announces First Quarter 2022 Operating And Financial Results
reuters.com · 05/05 20:33
More
No Data
Learn about the latest financial forecast of PRQR. Analyze the recent business situations of Proqr Therapeuti through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
57.14%Buy
42.86%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average PRQR stock price target is 8.57 with a high estimate of 37.65 and a low estimate of 1.018.
High37.65
Average8.57
Low1.018
Current 0.6425
EPS
Actual
Estimate
-0.24-0.18-0.12-0.06
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 99
Institutional Holdings: 53.82M
% Owned: 75.49%
Shares Outstanding: 71.29M
TypeInstitutionsShares
Increased
25
4.71M
New
18
9.79M
Decreased
24
3.57M
Sold Out
9
507.91K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.99%
Pharmaceuticals & Medical Research
-0.16%
Key Executives
Chairman - Supervisory/Independent Director
Dinko Valerio
Chairman - Management/Chief Executive Officer
Daniel De Boer
Other
Theresa Heggie
Independent Director/Supervisory Board
Bart Filius
Independent Director/Supervisory Board
Alison Lawton
Independent Director/Supervisory Board
Antoine Papiernik
Independent Director/Supervisory Board
James Shannon
No Data
No Data
About PRQR
ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010, an RNA-based oligonucleotide for the treatment of cystic fibrosis (CF), QR-110, an oligonucleotide and for the treatment of Leber’s congenital amaurosis (LCA).

Webull offers kinds of ProQR Therapeutics NV stock information, including NASDAQ:PRQR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PRQR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PRQR stock methods without spending real money on the virtual paper trading platform.